AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35019175
Drug: Dronedarone 400
RxNorm normalized name: dronedarone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronedarone 400 mg twice daily
Trial: 32007138
Drug: Dabrafenib 150
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150 mg orally twice daily plus trametinib 2 mg orally once daily
Trial: 34009274
Drug: anti‐IL6 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti‐IL6 receptor (tocilizumab, n=21)
Trial: 34009274
Drug: CTLA‐4Ig treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTLA‐4Ig treatment
Trial: 35333346
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of minor clinical symptoms (slight vaginal bleeding or some abdominal cramps) at treatment start
Trial: 33181849
Drug: Propolis chewing
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis chewing gum, chewed twice daily for at least twenty minutes for two weeks
Trial: 33181849
Drug: Propolis mouthwash,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis mouthwash, rinsed twice daily for one minute for two weeks
Trial: 32452659
Drug: Clopidogrel hydrogen
RxNorm normalized name: Clopidogrel hydrogen sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel hydrogen sulfate tablets (75 mg) under fed conditions
Trial: 32452659
Drug: Clopidogrel hydrogen
RxNorm normalized name: Clopidogrel hydrogen sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel hydrogen sulfate tablets (75 mg) under fasted conditions
Trial: 32452659
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Plavix)
Trial: 34717692
Drug: Concurrent ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent ibrutinib 560 mg continuously plus venetoclax ramp-up to 400 mg over 5 weeks
Trial: 32636324
Drug: erenumab (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erenumab (dose change from 140 mg to 70 mg)
Trial: 32636324
Drug: erenumab (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erenumab (dose change from 70 mg to 140 mg)
Trial: 33198627
Drug: Dendrogram analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendrogram analysis of 34 individuals representing the seven L. radiata lines
Trial: 34002560
Drug: Moxibustion combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion combined with leflunomide tablets, applied at Sanyinjiao (SP 6), Shenshu (BL 23), Zusanli (ST 36) and ashi points, once every other day, three times a week for 8 weeks.
Trial: 34002560
Drug: Leflunomide tablets
RxNorm normalized name: Leflunomide Tablets
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide tablets taken orally, once a day for 8 weeks.
Trial: 34237553
Drug: Animal Assisted
RxNorm normalized name: animals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal Assisted Therapy (AAT)
Trial: 34128766
Drug: Measles Containing
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles Containing Vaccines (MCVs)
Trial: 33053116
Drug: G‐CSF (granulocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (granulocyte colony‐stimulating factor)
Trial: 32097252
Drug: ART delivered
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART delivered three-monthly in CARGs (3MC)
Trial: 32097252
Drug: ART delivered
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART delivered six-monthly in CARGs (6MC)
Trial: 32097252
Drug: ART collected
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART collected three-monthly at facility (3MF)
Trial: 36370907
Drug: Ritlecitinib 50
RxNorm normalized name: ritlecitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 50 mg with loading dose
Trial: 36370907
Drug: Ritlecitinib 50
RxNorm normalized name: ritlecitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 50 mg without loading dose
Trial: 37707764
Drug: Ritlecitinib 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 30 mg
Trial: 36370907
Drug: Ritlecitinib 200/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 200/50 mg in extension period
Trial: 33826641
Drug: Agent-based model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent-based model with refined parameter estimation methods
Trial: 36436883
Drug: BLI/WBT (Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI/WBT (Behavioral Lifestyle Intervention followed by Well-Being Therapy)
Trial: 33579265
Drug: Atractylodes lancea
RxNorm normalized name: Atractylodes Lancea Root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atractylodes lancea extract (AL) at a single oral dose of 1000 mg
Trial: 33579265
Drug: Atractylodes lancea
RxNorm normalized name: Atractylodes Lancea Root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atractylodes lancea extract (AL) at multiple dosing of 1000 mg for 21 days
Trial: 32243274
Drug: 19 G
RxNorm normalized name: Sharps Collector 19 Gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19 G EBUS needle
Trial: 32243274
Drug: 21 G
RxNorm normalized name: Long's Lancets, 21 ga
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 G EBUS needle
Trial: 34423649
Drug: Ticagrelor pooled
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor pooled (60 or 90 mg BID)
Trial: 34155568
Drug: Brivaracetam 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 200 mg/day
Trial: 32021219
Drug: Personal Construct
RxNorm normalized name: Alstonia constricta bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal Construct Therapy (PCT)
Trial: 32747190
Drug: Concurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent treatment with pemetrexed plus cisplatin along with EGFR-TKI
Trial: 32747190
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with EGFR-TKI followed by chemotherapy after progression
Trial: 35253334
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg/day
Trial: 33020134
Drug: Hypoglycemia (HypoEx)
RxNorm normalized name: Drugs for treatment of hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia (HypoEx) with blood glucose (BG)≤3.9 mmol/L
Trial: 33020134
Drug: Euglycemia (EuEx)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemia (EuEx) with BG≥4.0, BG≤10.0 mmol/L
Trial: 34606988
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy duration (2 weeks vs. 8 weeks)
Trial: 37149056
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus placebo
Trial: 34774197
Drug: ChAdOx1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 plus cellular quadrivalent influenza vaccine
Trial: 34774197
Drug: BNT162b2 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 plus cellular quadrivalent influenza vaccine
Trial: 34774197
Drug: BNT162b2 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 plus MF59C adjuvanted, trivalent influenza vaccine
Trial: 34774197
Drug: ChAdOx1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 plus recombinant quadrivalent influenza vaccine
Trial: 34774197
Drug: ChAdOx1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 plus MF59C adjuvanted, trivalent influenza vaccine
Trial: 34774197
Drug: BNT162b2 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 plus recombinant quadrivalent influenza vaccine
Trial: 34774197
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of COVID-19 and influenza vaccines
Trial: 34774197
Drug: Concomitant vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant vaccination with ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine
Trial: 32820000
Drug: Leucocyte-rich PRP
RxNorm normalized name: HEMOPHILUS B PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucocyte-rich PRP (LR-PRP) injection
Trial: 32089371
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training based on international physical activity recommendations (PAR group)
Trial: 35297659
Drug: LT3 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LT3 treatment (0.8 μg/kg i.v. bolus followed by 0.113 μg/kg/h i.v. infusion for 48 hours)
Trial: 35572853
Drug: LT3 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LT3 treatment
Trial: 33796965
Drug: Compound topical
RxNorm normalized name: benzoin compound TOPICAL TINCTURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound topical anesthetic (CTA) combined with photobiomodulation therapy (PBMT)
Trial: 32729014
Drug: Tenofovir Disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir Disoproxil Fumarate (TDF) 245 mg/day
Trial: 32151227
Drug: Inorganic nitrate
RxNorm normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inorganic nitrate drink (140-ml beetroot juice per day)
Trial: 34972894
Drug: Pythagorean Self‐Awareness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pythagorean Self‐Awareness Intervention (PSAI) for 8 weeks along with continuous positive airway pressure (CPAP) treatment
Trial: 34972894
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) treatment alone
Trial: 33674871
Drug: ALB 400
RxNorm normalized name: darbepoetin alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ALB 400 mg
Trial: 33674871
Drug: ALB 800
RxNorm normalized name: darbepoetin alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ALB 800 mg
Trial: 33232804
Drug: Colchicine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.5 mg twice daily)
Trial: 35620986
Drug: Oral bicarbonate
RxNorm normalized name: sodium bicarbonate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bicarbonate (n=78)
Trial: 35620986
Drug: Intravenous bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bicarbonate (n=82)
Trial: 34033648
Drug: Dexamethasone 6
RxNorm normalized name: dexamethasone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 6 mg QD for 7 to 10 days
Trial: 34033648
Drug: Methylprednisolone 250
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 250 to 500 mg daily for 3 days followed by oral prednisone 50 mg daily for 14 days
Trial: 35699377
Drug: Lurasidone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone monotherapy
Trial: 32331053
Drug: Placebo (adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (adjunctive therapy)
Trial: 32331053
Drug: Adjunctive lurasidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive lurasidone (recurrence prevention study)
Trial: 32331053
Drug: Adjunctive placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive placebo (recurrence prevention study)
Trial: 34168425
Drug: Cold intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold intraoperative irrigating solution (2.7±0.1°C)
Trial: 34168425
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature irrigating solution (20.0±0.1°C)
Trial: 35491738
Drug: Topical ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ivermectin
Trial: 33881605
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment followed by skin surface application of a cosmeceutical containing growth factors (GFs) and Vitamin C
Trial: 32471651
Drug: Overall randomised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall randomised controlled trials in oral and maxillofacial surgery
Trial: 35964661
Drug: Delivery room
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivery room insertion of etonogestrel contraceptive implant (0-2 hours post-delivery)
Trial: 35964661
Drug: Delayed insertion
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed insertion of etonogestrel contraceptive implant (24-48 hours post-delivery)
Trial: 35964661
Drug: Delivery room
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivery room insertion of etonogestrel contraceptive implant
Trial: 35964661
Drug: Delayed insertion
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed insertion of etonogestrel contraceptive implant
Trial: 34726708
Drug: Lower-dose amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lower-dose amoxicillin (35-50 mg/kg/d)
Trial: 34726708
Drug: Higher-dose amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-dose amoxicillin (70-90 mg/kg/d)
Trial: 34726708
Drug: Lower-dose amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lower-dose amoxicillin in severe CAP
Trial: 34726708
Drug: Higher-dose amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-dose amoxicillin in severe CAP
Trial: 34726708
Drug: 3-day treatment
RxNorm normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day treatment in severe CAP
Trial: 34726708
Drug: 7-day treatment
RxNorm normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day treatment in severe CAP
Trial: 35381377
Drug: Weekly shipments
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly shipments of five breakfast and lunch meals that mimic school meals
Trial: 35381377
Drug: Weekly newsletter
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly newsletter on community resources
Trial: 35089373
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 50 mg
Trial: 35089373
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 200 mg
Trial: 34753843
Drug: Mini implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini implants
Trial: 32113628
Drug: Adjuvanted RSV
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted RSV vaccine
Trial: 33857411
Drug: Lobaplatin-based induction
RxNorm normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobaplatin-based induction chemotherapy (lobaplatin 30 mg/m2 on days 1 and 22, fluorouracil 800 mg/m2 on days 1-5 and 22-26 for two cycles) followed by concurrent lobaplatin-based chemoradiotherapy.
Trial: 33857411
Drug: Cisplatin-based induction
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based induction chemotherapy (cisplatin 100 mg/m2 on days 1 and 22, fluorouracil 800 mg/m2 on days 1-5 and 22-26 for two cycles) followed by concurrent cisplatin-based chemoradiotherapy.
Trial: 33857411
Drug: Lobaplatin-based induction
RxNorm normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobaplatin-based induction chemotherapy (lobaplatin 30 mg/m2) in per-protocol population.
Trial: 33857411
Drug: Cisplatin-based induction
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based induction chemotherapy (cisplatin 100 mg/m2) in per-protocol population.
Trial: 36964977
Drug: Insulin dose
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin dose
Trial: 38484209
Drug: Targeted agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted agents
Trial: 36385038
Drug: PCIA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCIA with low basal infusion
Trial: 36385038
Drug: PCIA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCIA with no basal infusion
Trial: 33759742
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy for social anxiety disorder in adolescents (CT‐SAD‐A)
Trial: 34610572
Drug: ZIKV-Ig (50.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZIKV-Ig (50.0 mL intravenous dose)
Trial: 34370331
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (CG) - no treatment
Trial: 36168148
Drug: Riluzole oral
RxNorm normalized name: riluzole Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole oral film (ROF) 50 mg
Trial: 36168148
Drug: Riluzole tablets
RxNorm normalized name: Riluzole Tablets
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riluzole tablets 50 mg
Trial: 36168148
Drug: Riluzole oral
RxNorm normalized name: riluzole Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole oral film (ROF) 50 mg with food
Trial: 34688917
Drug: Pioglitazone (PPAR-γ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PPAR-γ agonist) adjunctive to cognitive-behavioral therapy (CBT)
Trial: 34628066
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) therapy using a 670-nm light-emitting eye patch, applied for 90 seconds twice daily for 4 months.
Trial: 34628066
Drug: Placebo using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo using an identical device emitting broad-spectrum white light at low power, applied for 90 seconds twice daily for 4 months.
Trial: 33095939
Drug: Pomegranate fruit
RxNorm normalized name: Pomegranate Fruit
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate fruit extract (PFE) 1000 mg once daily for twelve months
Trial: 35951068
Drug: Thymosin α1
RxNorm normalized name: chymosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin α1 plus blood purification (BP) therapy
Trial: 35951068
Drug: Blood purification
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood purification (BP) treatment only
Trial: 32871870
Drug: PPI (Omeprazole;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI (Omeprazole; 40 mg twice daily)
Trial: 32303499
Drug: Monthly ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly ranibizumab 0.3 mg every 4 weeks
Trial: 35869988
Drug: Nicotine pouches
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine pouches (NPs) with 1.5 mg nicotine
Trial: 35869988
Drug: Nicotine pouches
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine pouches (NPs) with 2 mg nicotine
Trial: 35869988
Drug: Nicotine pouches
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine pouches (NPs) with 3.5 mg nicotine
Trial: 35869988
Drug: Nicotine pouches
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine pouches (NPs) with 8 mg nicotine
Trial: 616873944
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management with interventional therapy
Trial: 33010241
Drug: Efavirenz 400
RxNorm normalized name: efavirenz 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 400 mg
Trial: 33130059
Drug: Vancomycin solution
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin solution (5 mg/mL) soaking for 30 minutes
Trial: 35358738
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin
Trial: 35732845
Drug: 4 oz
RxNorm normalized name: Oval Amber 4 oz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 oz prunes daily plus docusate sodium 100 g twice daily